APC Anti-Human CD122/IL-2RB Antibody [TU27] (AGEL1781)
- SKU:
- AGEL1781
- Product Type:
- Antibody
- Antibody Type:
- Monoclonal Antibody
- Reactivity:
- Human
- Applications:
- FC
Frequently bought together:
Description
Product Title: | APC Anti-Human CD122/IL-2RB Antibody [TU27] |
SKU: | AGEL1781 |
Size: | 20 Tests, 100 Tests, 200 Tests |
Clone No: | TU27 |
Synonyms: | Interleukin-2 receptor subunit beta;IL-2RB;p75;CD122;IL-2Rβ; |
Host Species: | Mouse |
Reactivity: | Human |
Application: | FCM |
Isotype: | Mouse IgG1, κ |
Isotype Control: | APC Mouse IgG1, κ Isotype Control[MOPC-21] |
Form: | Liquid |
Conjugation: | APC |
Recommended Use: | Each lot of this antibody is quality control tested by flow cytometric analysis. The amount of the reagent is suggested to be used 5 µL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use. |
Spectrum: |
Swissprot: | P14784 |
Gene ID: | 3560 |
Storage Buffer: | Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer and 1% protein protectant. |
Stability & Storage: | Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase. |
Background: | CD122 is a 70-75 kD type I transmembrane glycoprotein and member of the Ig superfamily. It is IL-2 receptor β chain also known as IL-2Rβ, which is also shared by the IL-15 receptor. CD122 is constitutively expressed by NK cells and at lower levels by a subset of T cells. Its expression is upregulated upon activation. The IL-2Rβ chain can combine with either the common γ subunit (γc, CD132) alone or with the γc subunit and the IL-2Rα subunit (CD25) to generate intermediate or high affinity IL-2 receptor complexes, respectively. CD122 expression levels can be upregulated by activation. |